7 results on '"Röckmann-Helmbach H"'
Search Results
2. Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Maurer, M. (Marcus), Aberer, W. (W.), Agondi, R. (Rosana), Al-Ahmad, M. (Mona), Al-Nesf, M.A. (Maryam Ali), Ansotegui, I.J. (I.), Arnaout, R. (Rand), Arruda, L.K. (Luisa Karla), Asero, R. (Riccardo), Aygören-Pürsü, E. (Emel), Banerji, A. (Aleena), Bauer, A. (Andrea), Ben-Shoshan, M. (Moshe), Berardi, A. (Alejandro), Bernstein, J.A. (Jonathan A.), Betschel, S. (Stephen), Bindslev-Jensen, C. (Carsten), Bizjak, M. (Mojca), Boccon-Gibod, I. (Isabelle), Bork, K. (Konrad), Bouillet, L. (Laurence), Boysen, H.B. (Henrik Balle), Brodszki, N. (N.), Broesby-Olsen, S. (Sigurd), Busse, P. (Paula), Buttgereit, T. (Thomas), Bygum, A. (Anette), Caballero, T. (Teresa), Campos, R.A. (Régis A.), Cancian, M. (Mauro), Cherrez-Ojeda, I. (Ivan), Cohn, D.M. (Danny M.), Costa, C. (Célia), Craig, T., Criado, P.R. (Paulo Ricardo), Criado, R.F. (Roberta F.), Csuka, D. (Dorottya), Dissemond, J. (Joachim), Du-Thanh, A. (Aurélie), Ensina, L.F. (Luis Felipe), Ertaş, R. (Ragıp), Fabiani, J.E. (José E.), Fantini, C. (Claudio), Farkas, H. (Henriette), Ferrucci, S.M. (Silvia Mariel), Figueras-Nart, I. (Ignasi), Fili, N.L. (Natalia L.), Fomina, D. (Daria), Fukunaga, A. (Atsushi), Gelincik, A. (Asli), Giménez-Arnau, A., Godse, K., Gompels, M. (Mark), Gonçalo, M. (Margarida), Gotua, M. (M.), Gower, R. (Richard), Grumach, A.S. (Anete S.), Guidos-Fogelbach, G. (Guillermo), Hide, M. (Michihiro), Ilina, N. (Natalia), Inomata, N. (Naoko), Jakob, T. (Thilo), Josviack, D.O. (Dario O.), Kang, H.-R. (Hye-Ryun), Kaplan, A. (Allen), Kasperska-Zając, A. (Alicja), Katelaris, C. (Constance), Kessel, A. (Aharon), Kleinheinz, A. (Andreas), Kocatürk, E., Košnik, M. (Mitja), Krasowska, D. (Dorota), Kulthanan, K. (Kanokvalai), Kumaran, M.S. (M. Sendhil), Larco Sousa, J.I. (José Ignacio), Longhurst, H.J. (Hilary J.), Lumry, W. (William), MacGinnitie, A. (Andrew), Magerl, M. (Markus), Makris, M.P. (Michael P.), Malbrán, A. (Alejandro), Marsland, A. (Alexander), Martinez-Saguer, I. (Inmaculada), Medina, I.V. (Iris V.), Meshkova, R. (Raisa), Metz, M. (Martin), Nasr, I. (Iman), Nicolay, J. (Jan), Nishigori, C. (Chikako), Ohsawa, I. (Isao), Özyurt, K. (Kemal), Papadopoulos, N., Parisi, C.A.S. (Claudio A. S.), Peter, J.G. (Jonathan Grant), Pfützner, W. (W.), Popov, T.A., Prior, N. (Nieves), Ramon, G.D. (German D.), Reich, A. (Adam), Reshef, A. (Avner), Riedl, M.A. (Marc A.), Ritchie, B. (Bruce), Röckmann-Helmbach, H. (Heike), Rudenko, M. (Michael), Salman, A. (Andaç), Sanchez-Borges, M. (Mario), Schmid-Grendelmeier, P. (Peter), Serpa, F.S. (Faradiba S.), Serra-Baldrich, E. (Esther), Sheikh, F.R. (Farrukh R.), Smith, W. (William), Soria, A. (Angèle), Staubach, P. (Petra), Steiner, U.C. (Urs C.), Stobiecki, M. (Marcin), Sussman, G. (Gordon), Tagka, A. (Anna), Thomsen, S.F. (Simon Francis), Treudler, R. (Regina), Valle, S. (Solange), Doorn, M.B.A. (Martijn) van, Varga, L. (Lilian), Vázquez, D.O. (Daniel O.), Wagner, N. (Nicola), Wang, L. (Liangchun), Weber-Chrysochoou, C. (Christina), Ye, Y.-M. (Young-Min), Zalewska-Janowska, A. (Anna), Zanichelli, A. (Andrea), Zhao, Z. (Zuotao), Zhi, Y. (Yuxiang), Zuberbier, T. (Torsten), Zwiener, R.D. (Ricardo D.), Castaldo, A. (Anthony), Maurer, M. (Marcus), Aberer, W. (W.), Agondi, R. (Rosana), Al-Ahmad, M. (Mona), Al-Nesf, M.A. (Maryam Ali), Ansotegui, I.J. (I.), Arnaout, R. (Rand), Arruda, L.K. (Luisa Karla), Asero, R. (Riccardo), Aygören-Pürsü, E. (Emel), Banerji, A. (Aleena), Bauer, A. (Andrea), Ben-Shoshan, M. (Moshe), Berardi, A. (Alejandro), Bernstein, J.A. (Jonathan A.), Betschel, S. (Stephen), Bindslev-Jensen, C. (Carsten), Bizjak, M. (Mojca), Boccon-Gibod, I. (Isabelle), Bork, K. (Konrad), Bouillet, L. (Laurence), Boysen, H.B. (Henrik Balle), Brodszki, N. (N.), Broesby-Olsen, S. (Sigurd), Busse, P. (Paula), Buttgereit, T. (Thomas), Bygum, A. (Anette), Caballero, T. (Teresa), Campos, R.A. (Régis A.), Cancian, M. (Mauro), Cherrez-Ojeda, I. (Ivan), Cohn, D.M. (Danny M.), Costa, C. (Célia), Craig, T., Criado, P.R. (Paulo Ricardo), Criado, R.F. (Roberta F.), Csuka, D. (Dorottya), Dissemond, J. (Joachim), Du-Thanh, A. (Aurélie), Ensina, L.F. (Luis Felipe), Ertaş, R. (Ragıp), Fabiani, J.E. (José E.), Fantini, C. (Claudio), Farkas, H. (Henriette), Ferrucci, S.M. (Silvia Mariel), Figueras-Nart, I. (Ignasi), Fili, N.L. (Natalia L.), Fomina, D. (Daria), Fukunaga, A. (Atsushi), Gelincik, A. (Asli), Giménez-Arnau, A., Godse, K., Gompels, M. (Mark), Gonçalo, M. (Margarida), Gotua, M. (M.), Gower, R. (Richard), Grumach, A.S. (Anete S.), Guidos-Fogelbach, G. (Guillermo), Hide, M. (Michihiro), Ilina, N. (Natalia), Inomata, N. (Naoko), Jakob, T. (Thilo), Josviack, D.O. (Dario O.), Kang, H.-R. (Hye-Ryun), Kaplan, A. (Allen), Kasperska-Zając, A. (Alicja), Katelaris, C. (Constance), Kessel, A. (Aharon), Kleinheinz, A. (Andreas), Kocatürk, E., Košnik, M. (Mitja), Krasowska, D. (Dorota), Kulthanan, K. (Kanokvalai), Kumaran, M.S. (M. Sendhil), Larco Sousa, J.I. (José Ignacio), Longhurst, H.J. (Hilary J.), Lumry, W. (William), MacGinnitie, A. (Andrew), Magerl, M. (Markus), Makris, M.P. (Michael P.), Malbrán, A. (Alejandro), Marsland, A. (Alexander), Martinez-Saguer, I. (Inmaculada), Medina, I.V. (Iris V.), Meshkova, R. (Raisa), Metz, M. (Martin), Nasr, I. (Iman), Nicolay, J. (Jan), Nishigori, C. (Chikako), Ohsawa, I. (Isao), Özyurt, K. (Kemal), Papadopoulos, N., Parisi, C.A.S. (Claudio A. S.), Peter, J.G. (Jonathan Grant), Pfützner, W. (W.), Popov, T.A., Prior, N. (Nieves), Ramon, G.D. (German D.), Reich, A. (Adam), Reshef, A. (Avner), Riedl, M.A. (Marc A.), Ritchie, B. (Bruce), Röckmann-Helmbach, H. (Heike), Rudenko, M. (Michael), Salman, A. (Andaç), Sanchez-Borges, M. (Mario), Schmid-Grendelmeier, P. (Peter), Serpa, F.S. (Faradiba S.), Serra-Baldrich, E. (Esther), Sheikh, F.R. (Farrukh R.), Smith, W. (William), Soria, A. (Angèle), Staubach, P. (Petra), Steiner, U.C. (Urs C.), Stobiecki, M. (Marcin), Sussman, G. (Gordon), Tagka, A. (Anna), Thomsen, S.F. (Simon Francis), Treudler, R. (Regina), Valle, S. (Solange), Doorn, M.B.A. (Martijn) van, Varga, L. (Lilian), Vázquez, D.O. (Daniel O.), Wagner, N. (Nicola), Wang, L. (Liangchun), Weber-Chrysochoou, C. (Christina), Ye, Y.-M. (Young-Min), Zalewska-Janowska, A. (Anna), Zanichelli, A. (Andrea), Zhao, Z. (Zuotao), Zhi, Y. (Yuxiang), Zuberbier, T. (Torsten), Zwiener, R.D. (Ricardo D.), and Castaldo, A. (Anthony)
- Published
- 2020
- Full Text
- View/download PDF
3. [An exceptional venous pattern in a patient with cancer].
- Author
-
Franken MD, Röckmann-Helmbach H, and Bijlsma RM
- Subjects
- Female, Humans, Aged, Carboplatin therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel therapeutic use, Carcinosarcoma drug therapy, Endometrial Neoplasms complications, Endometrial Neoplasms drug therapy
- Abstract
A 71-year-old female was treated with carboplatin and paclitaxel for an endometrial carcinosarcoma. The patient demonstrated an unusual type 1 allergic reaction on carboplatin, which started with an erythematous urticarial venous pattern proximal from the venous catheter with carboplatin.
- Published
- 2023
4. Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy.
- Author
-
Broos N, Brigitha LJ, Schuurhof A, Röckmann-Helmbach H, Tissing WJE, Pieters R, van der Sluis IM, and Stadermann MB
- Abstract
Background: Children treated for a malignancy are at risk to develop serious illness from a COVID-19 infection. Pegylated E. coli asparaginase (PEG-asparaginase) is used in the treatment of acute lymphoblastic leukemia. Allergy to this drug is common and both asparaginase and polyethylene glycol (PEG) are identified as possible antigens. The mRNA-based vaccines against COVID-19 contain PEG as a stabilizing component., Methods: We developed a protocol to be able to safely vaccinate children with a PEG-asparaginase allergy. All patients with a history of allergy to PEG-asparaginase have been included and skin prick testing for various PEGs was performed before vaccination with the mRNA Pfizer-BioNTech COVID-19 vaccine., Results: Twelve children between six and 16 years old were vaccinated, without allergic reaction. None of them got a positive skin prick test for PEG. Ten patients had pre-existing IgG or IgM antibodies against PEG., Conclusion: Children with a PEG-asparaginase allergy can be safely vaccinated against COVID-19 with mRNA vaccines containing PEG irrespective of IgG/IgM antibodies to PEG-asparaginase. Routine skin prick testing in patients with PEG-asparaginase allergy does not seem to be of added value., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
5. Causes of perioperative hypersensitivity reactions in the Netherlands from 2002 to 2014.
- Author
-
van de Ven AAJM, Oude Elberink JNG, Nederhoed V, van Maaren MS, Tupker R, and Röckmann-Helmbach H
- Subjects
- Humans, Netherlands epidemiology, Perioperative Period adverse effects, Anaphylaxis etiology, Drug Hypersensitivity diagnosis, Drug Hypersensitivity epidemiology, Drug Hypersensitivity etiology
- Published
- 2022
- Full Text
- View/download PDF
6. Definition, aims, and implementation of GA 2 LEN/HAEi Angioedema Centers of Reference and Excellence.
- Author
-
Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Ansotegui I, Arnaout R, Arruda LK, Asero R, Aygören-Pürsün E, Banerji A, Bauer A, Ben-Shoshan M, Berardi A, Bernstein JA, Betschel S, Bindslev-Jensen C, Bizjak M, Boccon-Gibod I, Bork K, Bouillet L, Boysen HB, Brodszki N, Broesby-Olsen S, Busse P, Buttgereit T, Bygum A, Caballero T, Campos RA, Cancian M, Cherrez-Ojeda I, Cohn DM, Costa C, Craig T, Criado PR, Criado RF, Csuka D, Dissemond J, Du-Thanh A, Ensina LF, Ertaş R, Fabiani JE, Fantini C, Farkas H, Ferrucci SM, Figueras-Nart I, Fili NL, Fomina D, Fukunaga A, Gelincik A, Giménez-Arnau A, Godse K, Gompels M, Gonçalo M, Gotua M, Gower R, Grumach AS, Guidos-Fogelbach G, Hide M, Ilina N, Inomata N, Jakob T, Josviack DO, Kang HR, Kaplan A, Kasperska-Zając A, Katelaris C, Kessel A, Kleinheinz A, Kocatürk E, Košnik M, Krasowska D, Kulthanan K, Kumaran MS, Larco Sousa JI, Longhurst HJ, Lumry W, MacGinnitie A, Magerl M, Makris MP, Malbrán A, Marsland A, Martinez-Saguer I, Medina IV, Meshkova R, Metz M, Nasr I, Nicolay J, Nishigori C, Ohsawa I, Özyurt K, Papadopoulos NG, Parisi CAS, Peter JG, Pfützner W, Popov T, Prior N, Ramon GD, Reich A, Reshef A, Riedl MA, Ritchie B, Röckmann-Helmbach H, Rudenko M, Salman A, Sanchez-Borges M, Schmid-Grendelmeier P, Serpa FS, Serra-Baldrich E, Sheikh FR, Smith W, Soria A, Staubach P, Steiner UC, Stobiecki M, Sussman G, Tagka A, Thomsen SF, Treudler R, Valle S, van Doorn M, Varga L, Vázquez DO, Wagner N, Wang L, Weber-Chrysochoou C, Ye YM, Zalewska-Janowska A, Zanichelli A, Zhao Z, Zhi Y, Zuberbier T, Zwiener RD, and Castaldo A
- Subjects
- Humans, Angioedema diagnosis, Angioedema epidemiology, Urticaria
- Published
- 2020
- Full Text
- View/download PDF
7. Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk.
- Author
-
van den Elzen MT, van Os-Medendorp H, Röckmann-Helmbach H, van Hoffen E, Lebens AF, van Doorn H, Klemans RJ, Bruijnzeel-Koomen CA, Hack CE, Kaufman L, Relan A, and Knulst AC
- Subjects
- Adult, Angioedemas, Hereditary drug therapy, Animals, Cattle, Complement C1 Inhibitor Protein therapeutic use, Female, Humans, Immunoglobulin E immunology, Male, Middle Aged, Milk Hypersensitivity diagnosis, Phenotype, Rabbits, Recombinant Proteins therapeutic use, Severity of Illness Index, Skin Tests, Young Adult, Angioedemas, Hereditary complications, Complement C1 Inhibitor Protein adverse effects, Milk adverse effects, Milk Hypersensitivity complications, Milk Hypersensitivity immunology, Recombinant Proteins adverse effects
- Abstract
Background: Recombinant human C1 inhibitor (rhC1INH) for on-demand treatment of hereditary angioedema is purified from milk of transgenic rabbits. It contains low amounts (<0.002%) of host-related impurities, which could trigger hypersensitivity reactions in patients with rabbit allergy (RA) and/or cow's milk allergy (CMA)., Objective: This study is an assessment of allergenicity and safety of rhC1INH in patients with RA and/or CMA., Methods: Patients with CMA and/or RA underwent skin prick test (SPT), intracutaneous test (ICT), and, when results for both were negative, subcutaneous (SC) challenge with up to 2100U (14 mL) rhC1INH. The negative predictive value of the skin test protocol was calculated, defined as the ratio of patients without systemic symptoms of hypersensitivity following SC challenge, over the number of patients having tested negative for both the SPT and the ICT. Adverse events after exposure to rhC1INH were recorded., Results: Twenty-six patients with RA and/or CMA were enrolled. Twenty-four had negative SPT and ICT results for rhC1INH, whereas 2 had negative SPT result but positive ICT result to rhC1INH (only the highest concentration). Twenty-two patients with negative SPT and ICT results underwent SC challenge. None developed allergic symptoms. Local treatment-emergent adverse events occurred in 7 patients (32%) after SC challenge. In 5 these were considered drug related. All were mild., Conclusions: None of the patients with negative SPT and ICT results for rhC1INH had allergic symptoms during rhC1INH challenge. The negative predictive value of the combination of SPT and ICT for the outcome of the SC challenge was 100% (95% CI, 84.6%-100%). SC administration of rhC1INH was well tolerated., (Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.